Riskpilot← Back to searchSign inGet full accessReapplix A/S
A/SActiveCVR 31261570Bregnerødvej 133, st.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20089 employees
Revenue 2024
DKK 885K
-51% vs 2023
EBITDA margin
-5062.7%
-100% vs 2023
Equity ratio
74.7%
Financial strength
Net profit 2024
DKK -45,1M
-5% vs 2023
| Revenue | DKK 885K | -51% |
| EBITDA | DKK -44,8M | -100% |
| Net profit | DKK -45,1M | -5% |
| Total assets | DKK 16,4M | -73% |
| Equity | DKK 12,3M | -79% |
| Employees | 9 | — |
Legal name
Reapplix A/S
CVR number
31261570
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. februar 2008
Share capital
DKK 9.171.494
Employees
9 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af tre bestyrelsesmedlemmer eller af selskabets administrerende direktør og bestyrelsesformanden i forening.
Company purpose
Selskabets formål er at drive en virksomhed der udvikler og sælger et device der producerer fibrin dressing til brug for sårpleje og dermed beslægtet virksomhed.
Address
Bregnerødvej 133, st.
Phone
+4588168066
Email
info@reapplix.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | -3.148 | -4.003 | -8.989 | 49 | 116 | 71 | 191 | 656 | 659 | 916 | 2.066 | 1.818 | 885 |
| Staff expenses | -2.629 | -1.935 | -811 | -2.611 | -4.990 | -6.002 | -6.941 | -0 | -0 | -0 | -0 | -0 | -11.049 | -8.732 |
| EBITDA | -4.999 | -5.083 | -4.814 | -11.600 | -17.145 | -18.044 | -18.787 | -30.205 | -44.588 | -25.342 | -24.107 | -23.474 | -22.356 | -44.805 |
| Depreciation & amort. | 62 | -62 | -30 | -37 | -35 | -5 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -5.061 | -5.145 | -4.843 | -11.637 | -17.179 | -18.050 | -18.787 | -30.205 | -44.588 | -25.342 | -24.107 | -23.474 | -22.356 | -44.805 |
| Net financials | -95 | -116 | 72 | 72 | 1 | -373 | -1.661 | -9.957 | -3.835 | -14.940 | -10.287 | -28.127 | -21.998 | -1.269 |
| Profit before tax | -5.157 | -5.260 | -4.772 | -11.565 | -17.178 | -18.423 | -20.448 | -40.162 | -91.994 | -36.462 | -34.394 | -51.601 | -44.354 | -46.074 |
| Tax | -0 | -2.391 | -1.164 | -2.806 | -3.461 | -3.434 | -3.213 | -2.209 | -2.377 | -1.787 | -1.762 | -1.598 | -1.286 | -1.016 |
| Net profit | -5.157 | -2.869 | -3.608 | -8.759 | -13.717 | -14.989 | -17.235 | -37.953 | -89.617 | -34.675 | -32.632 | -50.003 | -43.068 | -45.058 |
| Item | 2012 | 2013 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 948 | 24.075 | 18.629 | 10.441 | 17.544 | 23.849 | 7.696 | 18.975 | 30.639 | 55.514 | 79.270 | 28.364 | 61.949 | 16.418 |
| Equity | -814 | 21.283 | 17.675 | 8.916 | 15.299 | 325 | -16.909 | 8.935 | -18.460 | 41.669 | 72.666 | 23.351 | 57.524 | 12.272 |
| Long-term debt | 1.000 | 2.000 | 0 | 0 | 0 | 0 | 0 | 0 | 793 | 911 | 664 | 910 | 846 | 290 |
| Short-term debt | 762 | 792 | 953 | 1.525 | 2.245 | 23.523 | 24.605 | 10.040 | 48.307 | 12.934 | 5.940 | 4.102 | 3.579 | 3.856 |
| Total debt | 1.762 | 2.792 | 953 | 1.525 | 2.245 | 23.523 | 24.605 | 10.040 | 49.100 | 13.845 | 6.604 | 5.012 | 4.425 | 4.146 |
EBITDA margin
-5062.7%
This company
15.8%
Market median
-32142% vs market
20122024
Equity ratio
74.7%
This company
38.2%
Market median
+96% vs market
20122024
Return on equity
-367.2%
This company
18.4%
Market median
-2096% vs market
20122024
Net profit margin
-5091.3%
This company
8.1%
Market median
-62956% vs market
20122024
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20122024
Debt / equity
0.34×
This company
0.62×
Market median
+45% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-05-01 – 2013-12-31
- Annual report 2013Filed via CVR / Virk · Period 2012-05-01 – 2013-04-30
- Annual report 2012Filed via CVR / Virk · Period 2011-05-01 – 2012-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RL Management | Management | 2008 | — | — |
GN Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
MH Management | Management | 2018 | — | — |
NE Management | Management | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2010 | — | — | |
| Board of Directors | 2014 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2009 | — | — | |
| Chairman | 2013 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2013 | — | — | |
| Deputy Chairman | 2021 | — | — | |
| Board of Directors | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Danmarks Eksport- og Investeringsfond | Company | 15.0% | 15.0% | 2023 |
Novo Holdings A/S | Company | 15.0% | 15.0% | 2023 |
North-East Health Care Holding ApS | Company | 10.0% | 10.0% | 2023 |
MK VENTURES ApS | Company | 10.0% | 10.0% | 2024 |
| Individual | 10.0% | 10.0% | 2026 | |
| Individual | 5.0% | 5.0% | 2023 | |
SEED CAPITAL DENMARK II K/S | Company | 5.0% | 5.0% | 2026 |
| Individual | 5.0% | 5.0% | 2023 | |
VÆKSTFONDEN | Company | 15.0% | 15.0% | 2020 |
PreSeed Ventures A/S | Company | 5.0% | 5.0% | 2013 |
North-East Health Care Investment ApS | Company | 5.0% | 5.0% | 2023 |
| Individual | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Reapplix A/S Board members of Reapplix A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rasmus Lundquist | Management | 0 companies |
| Graeme Nigel Brookes | Chief Executive Officer | 0 companies |
| Morten Have-Rasmussen | Management | 0 companies |
| Niels Erik Holm | Management | 0 companies |
| Cyrille Yann Nicolas Petit | Board of Directors | 0 companies |
| Tonni Bülow-Nielsen | Board of Directors | 0 companies |
| Klaus Eldrup-Jørgensen | Chairman | 0 companies |
| Carsten Schou | Board of Directors | 0 companies |
| Ulf Lennart Rosén | Board of Directors | 0 companies |
| Richard Twomey | Chairman | 0 companies |
| Line Holten Reimer | Board of Directors | 0 companies |
| Peter Gerhard Friedrich Hentschel | Chairman | 0 companies |
| Kira Paniagua Rupprecht | Board of Directors | 0 companies |
| Samuel Levy | Board of Directors | 0 companies |
| Jørgen Ulrik Vejlsgaard | Board of Directors | 0 companies |
| Søren Møller | Board of Directors | 0 companies |
| Ulrik Spork | Deputy Chairman | 0 companies |
| Birgit Aagaard-Svendsen | Board of Directors | 0 companies |